meta|evidence oncology

Living systematic review and meta-analysis

metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population 2
mHNSCC - L1 - PDL1 positive 4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population 4
mHNSCC - L2 - PDL1 negative 2
mHNSCC - L2 - PDL1 positive 1
hepatocell cancer (HCC) 1

immune chekpoint inhibitors
anti-PD-(L)1
pembrolizumab based treatment
pembrolizumab alone

versus all
vs chemotherapy
vs Standard of Care (SoC)

study list
mapping
overview
meta-analysis
forest plot
NMA
excluded

Study		Exclusion reasons	Remarks	Reference(s)
Empty list - no studies excluded

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -